Over 200,000 people in India are living with Multiple Sclerosis Sanofi Genzyme, the specialty care global business unit of Sanofi, brings to India - Aubagio (Teriflunomide, 14 mg), from its international Multiple Sclerosis (MS) portfolio.

Multiple Sclerosis is a chronic debilitating disease of the nervous system with varied symptoms like weakness in the limbs, poor vision, fatigue or slurred speech. Aubagio (Teriflunomide, 14 mg) is the first original 'once-daily' oral 'disease-modifying therapy' (DMT) for Multiple Sclerosis to be approved in India. It offers an effective, safe and a convenient option that is indicated as a first-line treatment for relapsing forms of Multiple Sclerosis that must be taken once a day, with or without food.

Commenting on the launch, N. Rajaram, Managing Director, Sanofi India, said, "There are around two lakh people living with this disease in India. There are increasing numbers of cases being detected due to greater awareness and access to better diagnostic facilities.

Millions of patients depend on us for their healthcare needs, and as a health journey partner, we understand the many challenges that people with Multiple Sclerosis face." He added, "For over a decade Sanofi has invested in developing and delivering novel therapeutic solutions for treatment of Multiple Sclerosis around the world; and with that, we have now brought our original research product to India.

This product has the potential to offer an efficacious and convenient treatment regimen of just once a day oral tablet, vis- -vis common treatment options that are injectables. With Aubagio (Teriflunomide, 14 mg), we reiterate Sanofi Genzyme's commitment to improve and empower the lives of people with debilitating diseases in India."

Dr. Shalini Menon, Head - Medical Affairs, India & South Asia, Sanofi, said, "Aubagio (Teriflunomide, 14 mg) is a differentiated disease-modifying therapy, that blocks the enzyme involved in multiplication of overactive immune cells. When taken daily, Aubagio (Teriflunomide, 14 mg) reduces the number of overactive immune cells that cause the disease flare-ups, while still allowing normal immune cell activity to occur. It is important to note that Aubagio (Teriflunomide, 14 mg) has demonstrated consistent efficacy in reducing the frequency of relapses, delaying the accumulation of physical disability and, arresting further decrease in brain volume.

In addition, given its convenience as an oral medicine, Aubagio (Teriflunomide, 14 mg) encourages people with Multiple Sclerosis to continue with long-term treatment." First approved by the US FDA in 2012, Aubagio (Teriflunomide, 14 mg) has a strong global presence today with approvals in more than 81 countries.

It has been extensively studied in more than 5,500 patients with up to 13 years of clinical and follow-up studies with proven clinical efficacy, safety and tolerability outcomes.[3] Globally, more than 85,000 patients with Multiple Sclerosis are benefitting from the use of Aubagio.